[go: up one dir, main page]

ATE331719T1 - USE OF CRYSTAL FORMS OF 2-METHYLTHIENOBEZODIAZEPINES - Google Patents

USE OF CRYSTAL FORMS OF 2-METHYLTHIENOBEZODIAZEPINES

Info

Publication number
ATE331719T1
ATE331719T1 AT03077455T AT03077455T ATE331719T1 AT E331719 T1 ATE331719 T1 AT E331719T1 AT 03077455 T AT03077455 T AT 03077455T AT 03077455 T AT03077455 T AT 03077455T AT E331719 T1 ATE331719 T1 AT E331719T1
Authority
AT
Austria
Prior art keywords
methylthienobezodiazepines
crystal forms
crystal
forms
Prior art date
Application number
AT03077455T
Other languages
German (de)
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE331719(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE331719T1 publication Critical patent/ATE331719T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
AT03077455T 1995-03-24 1996-03-22 USE OF CRYSTAL FORMS OF 2-METHYLTHIENOBEZODIAZEPINES ATE331719T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
ATE331719T1 true ATE331719T1 (en) 2006-07-15

Family

ID=23621056

Family Applications (4)

Application Number Title Priority Date Filing Date
AT00203573T ATE251627T1 (en) 1995-03-24 1996-03-22 METHOD AND CRYSTAL FORMS OF 2-METHYLTHIENOBEZODIAZEPINES
AT96302000T ATE204280T1 (en) 1995-03-24 1996-03-22 CRYSTAL FORMS OF A THIENO(2,3-B)(1, 5)BENZODIAZEPINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF
AT03077455T ATE331719T1 (en) 1995-03-24 1996-03-22 USE OF CRYSTAL FORMS OF 2-METHYLTHIENOBEZODIAZEPINES
AT0902196A AT406771B (en) 1995-03-24 1996-03-22 NEW CRYSTALLINE FORM OF 2-METHYL-4- (4-METHYL-1-PIPERAZINYL) -1OH-THIENO (2,3-B) (1,5) -BENZODIAZEPINE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL AGENTS AND THE USE THEREOF

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT00203573T ATE251627T1 (en) 1995-03-24 1996-03-22 METHOD AND CRYSTAL FORMS OF 2-METHYLTHIENOBEZODIAZEPINES
AT96302000T ATE204280T1 (en) 1995-03-24 1996-03-22 CRYSTAL FORMS OF A THIENO(2,3-B)(1, 5)BENZODIAZEPINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT0902196A AT406771B (en) 1995-03-24 1996-03-22 NEW CRYSTALLINE FORM OF 2-METHYL-4- (4-METHYL-1-PIPERAZINYL) -1OH-THIENO (2,3-B) (1,5) -BENZODIAZEPINE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL AGENTS AND THE USE THEREOF

Country Status (48)

Country Link
US (1) US5736541A (en)
EP (3) EP1095941B1 (en)
JP (1) JPH11502535A (en)
KR (1) KR100399688B1 (en)
CN (1) CN1065536C (en)
AP (1) AP828A (en)
AR (2) AR002719A1 (en)
AT (4) ATE251627T1 (en)
AU (1) AU706471B2 (en)
BG (1) BG62619B1 (en)
BR (1) BR9607790A (en)
CA (1) CA2214005C (en)
CH (1) CH690579A5 (en)
CO (1) CO4650278A1 (en)
CZ (1) CZ292688B6 (en)
DE (4) DE69630324T2 (en)
DK (4) DK1095941T3 (en)
EA (1) EA000149B1 (en)
EE (1) EE03489B1 (en)
EG (1) EG23659A (en)
ES (3) ES2208220T3 (en)
FI (1) FI973750A7 (en)
GB (1) GB2313835B (en)
HU (1) HU224989B1 (en)
IL (1) IL117610A (en)
IS (1) IS1896B (en)
LT (1) LT4349B (en)
LU (1) LU90096B1 (en)
LV (1) LV12018B (en)
MY (1) MY114701A (en)
NO (1) NO314663B1 (en)
NZ (1) NZ306110A (en)
OA (1) OA10510A (en)
PA (1) PA8353701A1 (en)
PE (1) PE44897A1 (en)
PL (1) PL183723B1 (en)
PT (3) PT1095941E (en)
RO (1) RO118872B1 (en)
SE (1) SE9703205L (en)
SI (4) SI0733635T1 (en)
SK (1) SK284143B6 (en)
SV (1) SV1996000031A (en)
TR (1) TR199701017T1 (en)
TW (2) TW513432B (en)
UA (1) UA44765C2 (en)
WO (1) WO1996030375A1 (en)
YU (1) YU49478B (en)
ZA (2) ZA962344B (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
AU7013196A (en) * 1995-09-29 1997-04-17 Eli Lilly And Company Method for treating a tic disorder
CZ290198A3 (en) * 1996-03-11 1999-09-15 Eli Lilly And Company Pharmaceutical composition for insomnia
UA57727C2 (en) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Method for treating excessive aggression
CA2250155A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
US5929070A (en) * 1996-03-25 1999-07-27 Eli Lilly And Company Method for treating migraine pain with olanzapine
CN1494907A (en) * 1996-03-25 2004-05-12 Drug composition for curing pain
AU721338B2 (en) * 1996-03-25 2000-06-29 Eli Lilly And Company Method for treating pain
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
NZ334346A (en) * 1996-09-23 2000-05-26 Lilly Co Eli Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
DK1155696T3 (en) * 1997-04-15 2004-07-12 Lilly Co Eli Use of olanzapine in the manufacture of a drug for neuroprotection
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
AU759751B2 (en) * 1998-09-30 2003-05-01 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
FR2802101B1 (en) 1999-12-10 2003-02-28 Aventis Pharma Sa COMBINATION OF CYMEMAZINE AND AN ATYPICAL NEUROLEPTIC
EP1246827B1 (en) * 1999-12-28 2005-04-13 Cipla Limited New polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2002018390A1 (en) * 2000-08-31 2002-03-07 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
EP1440074A1 (en) * 2001-10-29 2004-07-28 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
EP1470130A2 (en) * 2001-12-24 2004-10-27 Sun Pharmaceuticals Industries Ltd. Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno 2,3-b 1,5 benzodiazepine
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
JP4906233B2 (en) * 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ Multi-component solid phase containing at least one active pharmaceutical ingredient
PL196814B1 (en) 2002-05-17 2008-02-29 Inst Farmaceutyczny Method of obtaining polymorphous form of i olansapine
WO2003101997A1 (en) 2002-05-31 2003-12-11 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
SI21270A (en) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Crystal forms of olanzapine and procedures for their preparation
PL202856B1 (en) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Method of obtaining pharmaceutically pure polymorphic form of I olanzapine
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
ATE352305T1 (en) * 2003-03-12 2007-02-15 Teva Pharma STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING DESLORATADINE
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
US20070148218A1 (en) * 2003-11-18 2007-06-28 Gordon Ryan D Olanzapine containing transdermal drug delivery compositions
PT1611139E (en) * 2003-12-22 2008-07-17 Teva Pharma Methods of preparing olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
EP1709053B1 (en) 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
ES2253091B1 (en) 2004-07-27 2007-02-01 Inke, S.A. MIXED SOLVATO OF OLANZAPINE, PROCEDURE FOR OBTAINING AND PROCEDURE OF OBTAINING THE FORM I OF OLANZAPINE FROM THE SAME.
WO2006027800A1 (en) * 2004-09-06 2006-03-16 Shasun Chemicals And Drugs Limited A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
EP1827374B1 (en) * 2004-11-16 2014-11-05 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
DK1838716T3 (en) 2005-01-05 2011-07-25 Lilly Co Eli Olanzapinpamota dihydrate
CZ200563A3 (en) * 2005-02-02 2006-10-11 Zentiva, A. S. Therapeutical composition containing olanzapin as active component and process for its preparation
KR20070113277A (en) * 2005-03-21 2007-11-28 닥터 레디스 레보러터리즈 리미티드 Method for preparing crystalline form I of olanzapine
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
ES2279715B1 (en) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. ORAL FORMULATION OF OLANZAPINE.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
AR063043A1 (en) * 2006-09-29 2008-12-23 Synthon Bv PHARMACEUTICAL COMPOSITION OF OLANZAPINA
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (en) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent The manner of production of basically clean variety of polymorphic olanzapine
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (en) * 2008-11-06 2011-08-31 齐鲁制药有限公司 Preparation method of anhydrous olanzapine crystal form II
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
HUE041981T2 (en) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Procedures for treating antipsychotic-induced weight gain
CN102093386B (en) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 A kind of method preparing Zyprexa crystal form II
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
JP6374387B2 (en) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． Antibody to risperidone hapten and use thereof
CN104755093B (en) * 2012-08-21 2018-11-16 詹森药业有限公司 Antibody to olanzapine hapten and use thereof
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
JP6440625B2 (en) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Methods and compositions for treating schizophrenia
CN103848847B (en) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 A kind of method that improvement prepares Olanzapine and its crystal formation II
JP6008734B2 (en) * 2012-12-20 2016-10-19 株式会社トクヤマ Olanzapine type II crystal production method
CN103145731B (en) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 Olanzapine crystal form and its preparation method and use
EP4465968A1 (en) 2022-01-20 2024-11-27 Teva Pharmaceuticals International GmbH Olanzapine, compositions thereof and methods of use thereof
AU2024208071A1 (en) 2023-01-10 2025-06-12 Medincell Sa Olanzapine compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
DK0582368T3 (en) * 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepine derivatives for the treatment of central nervous system disorders
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
EE9700232A (en) 1998-04-15
DE69630324D1 (en) 2003-11-13
NO974365D0 (en) 1997-09-22
WO1996030375A1 (en) 1996-10-03
LV12018A (en) 1998-04-20
SE9703205D0 (en) 1997-09-05
SI1445259T1 (en) 2006-10-31
CO4650278A1 (en) 1998-09-03
IS4564A (en) 1997-09-22
DK108997A (en) 1997-11-12
DK0733635T3 (en) 2001-10-08
EP0733635B1 (en) 2001-08-16
IL117610A (en) 2001-08-26
PT1095941E (en) 2004-02-27
ES2208220T3 (en) 2004-06-16
DE69636313T2 (en) 2007-05-31
KR100399688B1 (en) 2004-02-18
LU90096B1 (en) 1997-07-22
BG101900A (en) 1999-03-31
CN1065536C (en) 2001-05-09
SI9620040B (en) 2002-02-28
CZ300097A3 (en) 1997-12-17
ES2266719T3 (en) 2007-03-01
ATE251627T1 (en) 2003-10-15
GB2313835A (en) 1997-12-10
DE69630324T2 (en) 2004-07-29
BR9607790A (en) 1998-07-07
HU224989B1 (en) 2006-05-29
HUP9802824A2 (en) 1999-06-28
KR19980703188A (en) 1998-10-15
US5736541A (en) 1998-04-07
MX9707183A (en) 1997-11-29
EA000149B1 (en) 1998-10-29
TW513432B (en) 2002-12-11
AR002719A1 (en) 1998-04-29
EE03489B1 (en) 2001-08-15
EG23659A (en) 2007-03-26
AP828A (en) 2000-04-28
CZ292688B6 (en) 2003-11-12
DK1445259T3 (en) 2006-10-16
UA44765C2 (en) 2002-03-15
DE69636313D1 (en) 2006-08-10
EP0733635A1 (en) 1996-09-25
AU706471B2 (en) 1999-06-17
DE19681286T1 (en) 1998-04-02
SK284143B6 (en) 2004-10-05
TR199701017T1 (en) 1998-01-21
YU17796A (en) 1999-03-04
CH690579A5 (en) 2000-10-31
EP1095941A1 (en) 2001-05-02
CA2214005A1 (en) 1996-10-03
FI973750L (en) 1997-09-22
FI973750A0 (en) 1997-09-22
SI9620040A (en) 1998-06-30
EP1445259A1 (en) 2004-08-11
ZA962342B (en) 1997-09-22
NZ306110A (en) 1998-09-24
GB2313835B (en) 1998-09-16
NO314663B1 (en) 2003-04-28
ZA962344B (en) 1997-09-22
LV12018B (en) 1998-09-20
LT4349B (en) 1998-05-25
MY114701A (en) 2002-12-31
RO118872B1 (en) 2003-12-30
SV1996000031A (en) 1998-03-27
PA8353701A1 (en) 1998-09-18
PT1445259E (en) 2006-10-31
DE69614426D1 (en) 2001-09-20
YU49478B (en) 2006-05-25
LT97148A (en) 1998-01-26
DE69614426T2 (en) 2002-05-23
SE9703205L (en) 1997-09-05
AU5427996A (en) 1996-10-16
PT733635E (en) 2001-12-28
ATE204280T1 (en) 2001-09-15
CA2214005C (en) 2001-07-03
IL117610A0 (en) 1996-07-23
PE44897A1 (en) 1997-10-22
EP1095941B1 (en) 2003-10-08
SI0733635T1 (en) 2002-06-30
DK1095941T3 (en) 2004-02-16
FI973750A7 (en) 1997-09-22
CN1179160A (en) 1998-04-15
OA10510A (en) 2002-04-24
PL322501A1 (en) 1998-02-02
ATA902196A (en) 2000-01-15
HK1013988A1 (en) 1999-09-17
BG62619B1 (en) 2000-03-31
JPH11502535A (en) 1999-03-02
IS1896B (en) 2003-10-20
ES2159346T3 (en) 2001-10-01
EP1445259B1 (en) 2006-06-28
HUP9802824A3 (en) 2000-01-28
AP9701065A0 (en) 1997-10-31
AR010448A1 (en) 2000-06-28
EA199700262A1 (en) 1998-02-26
GB9719819D0 (en) 1997-11-19
TW442488B (en) 2001-06-23
NO974365L (en) 1997-09-22
AT406771B (en) 2000-08-25
SI1095941T1 (en) 2003-12-31
SK121897A3 (en) 1998-03-04
PL183723B1 (en) 2002-07-31

Similar Documents

Publication Publication Date Title
DE69636313D1 (en) Use of crystal forms of 2-methylthienobenzodiazepines
DE69634998D1 (en) Control of edges
DE69631647D1 (en) DETECTING POSSIBLE FRAUDULARY USE OF COMMUNICATION
DE69431880D1 (en) USE OF (2-IMIDAZOLIN-2-YL-AMINO) QUINOXALINE DERIVATIVES
DE69626729D1 (en) Combination of data values
DE69533361D1 (en) IMPLEMENTATION OF HYDROCARBONS
DE69628195D1 (en) USE OF XYLOGLUCANE DOTRANSGLYCOSYLASE
NL300284I2 (en) Crystal modification of
ATE172762T1 (en) USE OF ETHYLENEAMINES IN LIGNIN REMOVAL
DE69827393D1 (en) COSMETIC USE OF BIS-RESORCINOL-TRIAZINE DERIVATIVES
DE69531048D1 (en) USE OF STEROIDSULPHATASE INHIBITORS
DE69622942D1 (en) Liquid-crystal ANZEIGVORRICHTUNG
DE59610014D1 (en) Quartz crystal sensor
DE69618264D1 (en) Improvements in the manufacture of crystal substrates
DE69612725D1 (en) Crystal holder
DE59401861D1 (en) USE OF FERROCEN
DE69605708D1 (en) Purification of pentafluoroethane
DE69606449D1 (en) Growing silicon single crystal
DE19681567T1 (en) Liquid crystal composition
DE69515021D1 (en) Alignment of interferometers
DE69508469D1 (en) Oxide-garnet single crystal
DE69638046D1 (en) SELECTION OF UTILITY USING IGF MIRRORS
DE59607408D1 (en) Mixtures of monoazopyridone dyes
DE59308823D1 (en) Use of thioalkanions as flavorings
ATE210605T1 (en) USE OF SULFONAMIDS TO CONTROL BIOGROWTH

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1445259

Country of ref document: EP